- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Live-Attenuated RSV Vaccine Shows Immunogenicity in Children: Journal of Infectious Diseases
Respiratory syncytial virus (RSV) is a significant cause of lower respiratory illness (LRI) in pediatric populations. With the need for an effective vaccine, Ruth Karron and team have explored RSV/6120/ΔNS2/1030s, a cDNA-derived live-vaccine candidate. The findings were published in The Journal of Infectious Diseases.
To evaluate the safety and immunogenicity of the RSV/6120/ΔNS2/1030s vaccine, a double-blind, placebo-controlled trial was conducted. The trial administered a single intranasal dose of the vaccine at different levels of plaque-forming units (PFU) to two groups: 15 RSV-seropositive children aged 12 to 59 months and 30 RSV-seronegative children aged 6 to 24 months. The vaccine-to-placebo ratio was 2:1.
The study found that RSV/6120/ΔNS2/1030s was able to infect 100% of the RSV-seronegative children and demonstrated immunogenicity, as evidenced by the geometric mean RSV plaque-reduction neutralizing antibody titer (RSV-PRNT) of 1:91. Furthermore, the vaccine proved to be genetically stable. However, researchers observed mild rhinorrhea (runny nose) occurring more frequently in vaccinated children (18 out of 20) compared to those who received the placebo (4 out of 10) during the trial period. Notably, only one vaccinee experienced LRI during a period when only the vaccine virus was detected.
Following the RSV season, 5 out of 16 vaccinees exhibited significant rises (≥4-fold) in RSV-PRNT, with substantially higher titers compared to the 4 out of 10 placebo recipients with rises. This indicated that RSV/6120/ΔNS2/1030s primed for strong anamnestic (memory) neutralizing antibody responses following naturally-acquired RSV infection.
The RSV/6120/ΔNS2/1030s vaccine candidate has shown promise as an immunogenic and genetically stable option for RSV-seronegative children aged 6 to 24 months. It was able to induce primary neutralizing serum antibody responses and potent memory antibody responses in this population. However, the study also revealed a higher frequency of rhinorrhea in vaccinated children compared to those who received the placebo.
While the vaccine's safety profile warrants further investigation, the positive results in terms of immunogenicity and anamnestic responses provide hope for a potential solution to combat RSV in vulnerable pediatric populations.
Reference:
Karron, R. A., Luongo, C., Woods, S., Oliva, J., Collins, P. L., Buchholz, U. J., Council-Dibitetto, C., Gatto, M., Ghasri, T., Gormley, A., Herbert, K., Jordan, M., Loehr, K., Morsell, J., Soro, P., … Wanionek, K. (2023). Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/ΔNS2/1030s in RSV-seronegative young children. In The Journal of Infectious Diseases. Oxford University Press (OUP). https://doi.org/10.1093/infdis/jiad281
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751